Key Takeaway: David Freeman has been appointed as Senior Research Associate at Immuneering in 2026. He previously worked at Escient Pharmaceuticals, where he contributed to the development of the company's lead project. Freeman holds a B.S. in Biology from UCSD, enhancing his qualifications for his new role.
Price reaction · baseline $4.445 (2026-07-21T19:40:00.000Z) · hit during market hours · 1 other IMRX headline(s) in the window, move may be shared
day 0 close · peak
+0.3%
Market Sentiment Analysis
POSITIVE FACTORS
David Freeman has joined Immuneering as Senior Research Associate.
He has valuable experience from Escient Pharmaceuticals.
His background in high-throughput screening is beneficial.
Full Press Release Details
David joined Immuneering in 2026 as Senior Research Associate. Prior to joining Immuneering, David worked at Escient Pharmaceuticals, where he ran high-throughput screening and helped bring the company’s lead project to the clinic. David earned his B.S. in Biology from UCSD.
The post David Freeman appeared first on Immuneering Corporation .
Frequently Asked Questions
What position has David Freeman taken at Immuneering?
David Freeman has joined Immuneering as Senior Research Associate.
Where did David Freeman work before Immuneering?
Before Immuneering, David worked at Escient Pharmaceuticals.
What is David Freeman's educational background?
David earned his B.S. in Biology from UCSD.
What experience does David Freeman bring to Immuneering?
He has experience in high-throughput screening from his time at Escient.